PARTNER — Erisyon awarded $2.2M for cancer research
Using next generation DNA fluorosequencing technology, the Erisyon device runs billions of protein identification tests in parallel to deduce which cancer treatment will be the most effective for a specific patient. The Cancer Prevention and Research Institute of Texas has awarded this grant, partnering with Erisyon to target a biomarker associated with lung cancer.